AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
NeuroPace, Inc.
Video analysis: NPCE
All videosNo video analysis for this stock yet. Request one from our team.
News: NPCE
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE
Bank of America Corp DE reduced its stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) by 85.5% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 24,698 shares of the company's stock after selling 145,741 shares during the period. Bank of America Corp DE owned
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc.
BlackRock Inc. bought a new stake in NeuroPace, Inc. (NASDAQ: NPCE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,477,603 shares of the company's stock, valued at approximately $39,369,000. BlackRock Inc. owned about 7.27% of NeuroPace as of
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a.
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via.
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
